A novel latent catalytic process that transforms polyethylene terephthalate (PET) into an aqueously degradable polymer while retaining melt processability. The modified PET can be formulated to control degradation kinetics and is designed for compatibility with industrial polymer foaming processes such as foam cup manufacturing.
This solution introduces a latent catalytic approach that renders conventional polyethylene terephthalate (PET) degradable in aqueous environments without sacrificing melt processability. By embedding a latent catalyst or reactive additive into the PET matrix, the resulting material behaves like standard PET during melt processing and forming, yet can be broken down in water after disposal. The degradation rate can be tuned through formulation adjustments, offering a practical pathway to address the long-standing persistence of PET waste in the environment.
The technology targets packaging applications, with foam cups identified as a key near-term use case. By enabling PET foams that degrade on a useful timescale, the approach offers a drop-in alternative for manufacturers seeking sustainable material options without major retooling.
The technology is at an early-to-mid stage of development. Initial proof-of-concept work has demonstrated that PET can be chemically rendered degradable in water while remaining melt processable, with controllable degradation kinetics. Future validation efforts are focused on optimizing the formulation specifically for foam cup applications, including ensuring that the material meets processing requirements and achieves targeted degradation performance in real-world conditions.
Georgia Institute of Technology is a large, technology‑focused public research university in Atlanta with a strong applied research culture. Industry engages through the Georgia Tech Research Institute for contract R&D, a Midtown innovation district with co‑located corporate labs, and a statewide manufacturing extension to support scale‑up. A long‑standing partnership with a major academic medical center enables clinical translation, and a large co‑op program delivers a steady talent pipeline. Research is backed by competitive federal funding from NSF, NIH, DOE, DoD, and NASA. Technology commercialization is managed by the Georgia Tech Research Corporation, with dedicated licensing, corporate contracting, and startup support.